Nordion to manufacture NAV5001 agent for clinical trials

05/16/2013 | Pharmaceutical Business Review Online

Nordion has inked a deal with Navidea Biopharmaceuticals, agreeing to manufacture the imaging agent NAV5001 for Navidea's Phase IIb and Phase III trials expected to start this year. The agent is used in diagnosing Parkinsonian syndromes and dementia with Lewy bodies. The deal is initially effective for three years.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC